Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 19/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PLA2G10 | O15496 | 3/20 | 0.46 |
| ▸ | PLA2G1B | P04054 | 3/20 | 0.46 |
| ▸ | PLA2G5 | P39877 | 3/20 | 0.46 |
| ▸ | PLA2G2E | Q9NZK7 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6586773 | 0.92 | PLA2G2A (0.49) | PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G2E | |
| SCHEMBL6585606 | 0.89 | PLA2G2A (0.41) | PLA2G2AKDM4EALDH1A1SMN1; SMN2PLA2G10 | |
| SCHEMBL6590065 | 0.89 | ALDH1A1 (0.48) | PLA2G2AKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL6587633 | 0.81 | MAPT (0.39) | PLA2G2AKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL6585605 | 0.81 | PLA2G10 (0.42) | PLA2G2AKDM4EPLA2G10PLA2G1BPLA2G5 | |
| SCHEMBL6585857 | 0.80 | PDE5A (0.43) | PLA2G2AALDH1A1KMT2APLA2G1B | |
| SCHEMBL3344376 | 0.79 | PLA2G2A (0.55) | PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G2E | |
| SCHEMBL6588669 | 0.77 | TP53 (0.39) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL6586392 | 0.76 | POLB (0.40) | KDM4EMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL6599511 | 0.75 | THRB (0.45) | PLA2G2AKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6265421-B1 | DILATATION OF ARTERIES | ORION CORPORATION (FI) | 2001-07-24 | — | — | US | claimed |
| EP-1001774-B1 | USE OF PHOSPHOLAMBAN INHIBITORS FOR INCREASING CORONARY FLOW | ORION CORP (FI) | 2004-09-15 | — | — | EP | disclosed |
| US-6774103-B1 | Compounds for deactivating phospholamban function on Ca-ATPase (phospholamban inhibitors) | ORION CORPORATION (FI) | 2004-08-10 | — | — | US | disclosed |
| US-6538022-B1 | Three-dimensional structure of the cytosolic domain of phospholamban (PLB) and its active site from NMR data of sufficiently high resolution for the three-dimensional structure determination. rational drug design enabling the | ORION CORPORATION (FI) | 2003-03-25 | — | — | US | disclosed |
| EP-1039884-B1 | A METHOD FOR THE PREVENTION AND TREATMENT OF STUNNED MYOCARDIUM | ORION CORP (FI) | 2002-09-18 | — | — | EP | disclosed |
| US-6265421-B1 | DILATATION OF ARTERIES | ORION CORPORATION (FI) | 2001-07-24 | — | — | US | disclosed |
| EP-1039884-A1 | A METHOD FOR THE PREVENTION AND TREATMENT OF STUNNED MYOCARDIUM | ORION CORPORATION (FI) | 2000-10-04 | — | — | EP | disclosed |
| EP-1017691-A1 | BISETHERS OF 1-OXA, AZA AND THIANAPHTHALEN-2-ONES AS PHOSPHOLAMBAN INHIBITORS | ORION CORPORATION (ORION-YHTYMA OY) (FI) | 2000-07-12 | — | — | EP | disclosed |
| EP-1001774-A1 | USE OF PHOSPHOLAMBAN INHIBITORS TO INCREASING CORONARY FLOW | ORION CORPORATION (FI) | 2000-05-24 | — | — | EP | disclosed |
| US-5968959-A | ADMINISTERING PHOSPHOLAMBAN INHIBITOR | ORION CORPORATION (FI) | 1999-10-19 | — | — | US | disclosed |
| WO-1999030696-A1 | A METHOD FOR THE PREVENTION AND TREATMENT OF STUNNED MYOCARDIUM | ORION CORPORATION (FI) | 1999-06-24 | — | — | WO | disclosed |
| WO-1999015523-A1 | BISETHERS OF 1-OXA, AZA AND THIANAPHTHALEN-2-ONES AS PHOSPHOLAMBAN INHIBITORS | ORION CORPORATION (FI) | 1999-04-01 | — | — | WO | disclosed |
| WO-1999000132-A1 | USE OF PHOSPHOLAMBAN INHIBITORS FOR INCREASING CORONARY FLOW | ORION CORPORATION (FI) | 1999-01-07 | — | — | WO | disclosed |